Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 14,725 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $22.99, for a total transaction of $338,527.75. Following the completion of the transaction, the senior vice president now directly owns 6,395 shares of the company’s stock, valued at $147,021.05. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jamie Christensen also recently made the following trade(s):

  • On Thursday, November 16th, Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $184,950.00.
  • On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00.

Mirati Therapeutics, Inc. (MRTX) traded up $1.45 during trading on Thursday, hitting $23.20. 804,550 shares of the stock were exchanged, compared to its average volume of 387,470. Mirati Therapeutics, Inc. has a one year low of $2.70 and a one year high of $23.45. The firm has a market cap of $587.11, a P/E ratio of -7.46 and a beta of 1.79.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. research analysts expect that Mirati Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. Broadfin Capital LLC lifted its stake in Mirati Therapeutics by 19.1% in the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock valued at $9,091,000 after purchasing an additional 400,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Mirati Therapeutics by 53.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock valued at $728,000 after purchasing an additional 69,377 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at about $268,000. Jane Street Group LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at about $668,000. Finally, Goldman Sachs Group Inc. lifted its stake in Mirati Therapeutics by 845.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 87,858 shares during the last quarter. Institutional investors own 64.68% of the company’s stock.

MRTX has been the subject of a number of recent research reports. ValuEngine upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 16th. Cann restated a “buy” rating and set a $18.00 price objective on shares of Mirati Therapeutics in a research note on Monday. Oppenheimer set a $18.00 price objective on shares of Mirati Therapeutics and gave the stock a “buy” rating in a research note on Monday. HC Wainwright increased their price objective on shares of Mirati Therapeutics from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Cowen initiated coverage on shares of Mirati Therapeutics in a research note on Thursday, December 21st. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $14.75.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/mirati-therapeutics-inc-mrtx-svp-jamie-christensen-sells-14725-shares/1803580.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.